Pacific Biometrics Names New Controller; John Jensen to Create Strong Accounting Infrastructure to Meet Needs of Growing Lab Business

SEATTLE--(BUSINESS WIRE)--June 7, 2005--Pacific Biometrics, Inc. (OTCBB: PBME, "PBI") hired John Jensen as its new Controller. Jensen will play a key role in instituting cost accounting procedures to help the business operate more efficiently.

Jensen brings to PBI more than 25 years' experience in senior accounting and controller positions. Jensen joins PBI from Utility, Inc., where he served as Controller and Vice President of Operations and oversaw strategic planning and finance. He had previously worked at Seattle Lab, Inc. from 2000 to 2002 as its Director of Operations. Jensen has held several other relevant positions including Finance and IS Manager at Mountain Safety Research and Accounting Manager at Karr Tuttle Campbell, PS. Jensen earned a B.A. in business administration from Eastern Washington University in Cheney, Washington.

“Having smart, scalable cost accounting procedures in place will be essential as we actively grow the business by bringing new clients on board while also improving our margins.”

"Jensen has an extensive accounting and finance background and will help round out the management team," said Ron Helm, CEO of PBI. "Having smart, scalable cost accounting procedures in place will be essential as we actively grow the business by bringing new clients on board while also improving our margins."

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based laboratories approved and accredited by the Center for Disease Control (CDC) as a Cholesterol Reference Laboratory. PBI's clients include many of the world's largest pharmaceutical, biotech and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com or contact Ronald Helm, Chairman / CEO at 206-298-0068.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including to but not limited to our strategic planning and business development plans, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth and our investments in our infrastructure, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB, Forms 10-QSB and our Form SB-2 registration statements).